IceCure Medical Ltd (ICCM)
| Market Cap | 29.83M |
| Revenue (ttm) | 3.34M |
| Net Income (ttm) | -13.69M |
| Shares Out | 49.52M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 687,098 |
| Open | 0.600 |
| Previous Close | 0.610 |
| Day's Range | 0.593 - 0.620 |
| 52-Week Range | 0.480 - 1.570 |
| Beta | 2.63 |
| Analysts | Strong Buy |
| Price Target | 2.70 (+348.13%) |
| Earnings Date | Nov 26, 2024 |
About ICCM
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system ... [Read more]
Financial Performance
In 2023, IceCure Medical's revenue was $3.23 million, an increase of 4.67% compared to the previous year's $3.09 million. Losses were -$14.65 million, -13.70% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ICCM stock is "Strong Buy." The 12-month stock price forecast is $2.7, which is an increase of 348.13% from the latest price.
News
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
CAESAREA, Israel , Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing...
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and bre...
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
FDA decision on marketing authorization expected in the first quarter of 2025 CAESAREA, Israel , Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "...
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
Comments from key stakeholders, including doctors, nurses, researchers, and breast cancer patients, are available on FDA website FDA Advisory Panel providing recommendations and vote on information co...
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
Innovative cryogenic system connector technology designed to improve usability and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel , Oct. 21, 2024 /PRNewswire/ --...
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovich wins EUSOBI 2024 Abstract Award THERMAC Trial on Treatment of Breast Cancer with Percutaneous Thermal Ablation (cryo...
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer scheduled for November 7, 2024 96.3% recurrence free rate for w...
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage Independent study conducte...
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancer F DA ...
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
Company presentation to focus on how IceCure's industry-leading ProSense® enables non-surgical treatment of benign and cancerous tumors and upcoming n ear-term regulatory and operating catalysts CAE...
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies
Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fields Over 50 patents issued and allowed worldwide for IceCure's platform cryoablation ...
IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q2 2024 Earnings Call Transcript August 20, 2024 10:00 AM ET Company Participants Michael Polyviou - IR Shad Good - VP of North American Sales Ronen Tsimerman - CFO ...
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets
Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Easter...
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100% Study concluded that most non-surgical patients with early-stage breast cancer...
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024
CAESAREA, Israel , Aug. 13, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing...
IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"
Investigator initiated independent study included higher risk patients such as those with metastatic disease, large tumors, and comorbidities, as compared to IceCure's ICE3 study which treated early-s...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society
Demand for minimally invasive breast cancer treatment was overarching theme of the conference In one independent study led by Professor Fukuma, 389 patients treated for up to 10 years had 99.74% recur...
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
CAESAREA, Israel , July 19, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alt...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer
Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for breast cancer with low complication r...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes
CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024
Recent insider open-market stock purchases demonstrate continued confidence in the Company CAESAREA, Israel , June 18, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Me...
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rate More data is expected in the fourth quarte...
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan
Demonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer Patients, patient advocacy groups, doctors, and t...
IceCure Medical Ltd (ICCM) Q1 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q1 2024 Earnings Conference Call May 28, 2024 11:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer Tlalit Bus...
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024
30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3 tr...